Rigel Pharmaceuticals RIGL
NASDAQ RIGL
$47.15 +0.18 (+0.38%)
At close: Oct 2, 2026 · 4:00 PM EDT

Rigel Pharmaceuticals (RIGL) Gains from Sales and Divestitures (2014 - 2024)

Updated

Rigel Pharmaceuticals' Gains from Sales and Divestitures came in at $56,000 for Q4 2024, down 49.1% from $110,000 a year earlier.

Analysis

Rigel Pharmaceuticals (RIGL) Gains from Sales and Divestitures (2014 - 2024) Analysis & Trends

For FY2024, Rigel Pharmaceuticals' Gains from Sales and Divestitures was $79,000.

  • Going back by year, Gains from Sales and Divestitures was -$266,000 in FY2023 and $138,000 in FY2022.
  • The Q4 2024 figure represents the lowest quarterly Gains from Sales and Divestitures since Q3 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Rigel Pharmaceuticals 880.76 Mn 346.64 Mn 70.18 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 56,000.00
Dec 31, 2023 110,000.00
Sep 30, 2023 22,000.00
Jun 30, 2023 -51,000.00
Mar 31, 2023 -347,000.00
Dec 31, 2022 -327,000.00
Sep 30, 2022 212,000.00
Mar 31, 2017 732,000.00
Sep 30, 2015 55,000.00
Dec 31, 2014 52,000.00
Sep 30, 2014 44,000.00
API Access

Rigel Pharmaceuticals Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=RIGL&period=max&api_key=YOUR_API_KEY